IOL & survival

• In 467 MDS patients, TD patients had significantly shorter OS (p<0.001). Number of transfusions & transfusion rate were associated with OS (p<0.001). Also significant was SF >1000ng/mL, (p<0.001) with an HR for death of 1.36/500ng/mL SF increase >1000ng/mL¹.
• In 512 US Medicare MDS patients, TD was associated with a higher risk of death (adjusted HR 2.41, p<0.001)². Similarly, in an analysis from Spain, patients with an SF >1000ng/mL had inferior OS in the subtypes RA/RARS, RCMD/RCMD-RS, del(5q)MDS, RAEB1 & RAEB2 (p<0.014 for all)³.
• These studies are retrospective, and it is possible that the results are influenced by such factors as differences in disease biology; an analysis from the EUMDS addresses this point. In this analysis, survival of TD MDS patients with & without MDS progression was evaluated; in both cases, survival of TD patients was inferior⁴.